SK252004A3 - Použitie antagonistov receptora NK-1 na výrobu liečiva na liečenie abnormálneho úzkostného správania domácich zvierat a spôsob screeningu skúšanej zlúčeniny s cieľom stanoviť anxiolytickú účinnosť u psov - Google Patents

Použitie antagonistov receptora NK-1 na výrobu liečiva na liečenie abnormálneho úzkostného správania domácich zvierat a spôsob screeningu skúšanej zlúčeniny s cieľom stanoviť anxiolytickú účinnosť u psov Download PDF

Info

Publication number: SK252004A3
Authority: SK; Slovakia
Prior art keywords: phenylpiperidine; methoxybenzylamino; diphenylmethyl; azabicyclo; octane
Prior art date: 2001-07-20

Application number

SK25-2004A

Other languages

English (en)

Slovak (sk)

Inventor

Brian Scott Bronk

Mary Anne Hickman

Carolyn Rose Kilroy

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-20

Filing date

2002-07-15

Publication date

2005-03-04

2002-07-15 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2005-03-04 Publication of SK252004A3 publication Critical patent/SK252004A3/sk

Links

102000002002 Neurokinin-1 Receptors Human genes 0.000 title claims abstract description 40
108010040718 Neurokinin-1 Receptors Proteins 0.000 title claims abstract description 40
230000002159 abnormal effect Effects 0.000 title claims abstract description 39
241001465754 Metazoa Species 0.000 title claims abstract description 34
239000002464 receptor antagonist Substances 0.000 title claims abstract description 31
229940044551 receptor antagonist Drugs 0.000 title claims abstract description 31
230000006400 anxiety behaviour Effects 0.000 title claims abstract description 26
238000000034 method Methods 0.000 title claims abstract description 16
241000282472 Canis lupus familiaris Species 0.000 title claims description 68
150000001875 compounds Chemical class 0.000 title claims description 61
238000012360 testing method Methods 0.000 title claims description 39
230000000949 anxiolytic effect Effects 0.000 title claims description 13
239000003814 drug Substances 0.000 title claims description 10
238000012216 screening Methods 0.000 title claims description 8
238000004519 manufacturing process Methods 0.000 title claims description 4
238000011282 treatment Methods 0.000 title description 36
208000019901 Anxiety disease Diseases 0.000 claims description 27
238000000926 separation method Methods 0.000 claims description 27
-1 2-methoxy-5-methyl-benzylamino Chemical group 0.000 claims description 20
208000013403 hyperactivity Diseases 0.000 claims description 19
230000036506 anxiety Effects 0.000 claims description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
230000006378 damage Effects 0.000 claims description 7
230000029142 excretion Effects 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 5
DTQNEFOKTXXQKV-HKUYNNGSSA-N (2s,3s)-n-[(2-methoxyphenyl)methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)NCCC1 DTQNEFOKTXXQKV-HKUYNNGSSA-N 0.000 claims description 4
JASMWYNKLTULAN-UHFFFAOYSA-N octan-3-amine Chemical compound CCCCCC(N)CC JASMWYNKLTULAN-UHFFFAOYSA-N 0.000 claims description 4
230000007958 sleep Effects 0.000 claims description 4
125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 claims description 3
239000012530 fluid Substances 0.000 claims description 3
230000037406 food intake Effects 0.000 claims description 3
235000012631 food intake Nutrition 0.000 claims description 3
229910052757 nitrogen Inorganic materials 0.000 claims description 3
208000019899 phobic disease Diseases 0.000 claims description 3
CAWVBTFOZJKLOD-LAUBAEHRSA-N (2s,3s)-2-phenyl-3-[[2-propan-2-yloxy-5-(trifluoromethoxy)phenyl]methyl]piperidin-1-amine Chemical compound CC(C)OC1=CC=C(OC(F)(F)F)C=C1C[C@H]1[C@@H](C=2C=CC=CC=2)N(N)CCC1 CAWVBTFOZJKLOD-LAUBAEHRSA-N 0.000 claims description 2
PRXRQNXEYXMJCK-NSIYGSDQSA-N (2s,3s,4s,5r)-2-benzhydryl-3-[(2,5-dimethoxyphenyl)methylamino]-1-azabicyclo[2.2.2]octane-5-carboxylic acid Chemical compound C=1C=CC=CC=1C([C@@H]1N2CC[C@@]([C@H](C2)C(O)=O)([C@@H]1NCC=1C(=CC=C(OC)C=1)OC)[H])C1=CC=CC=C1 PRXRQNXEYXMJCK-NSIYGSDQSA-N 0.000 claims description 2
GKJVNRHHOMPGSG-NSIYGSDQSA-N (2s,3s,4s,5r)-2-benzhydryl-3-[(2-methoxy-5-methylphenyl)methylamino]-1-azabicyclo[2.2.2]octane-5-carboxylic acid Chemical compound C=1C=CC=CC=1C([C@@H]1N2CC[C@@]([C@H](C2)C(O)=O)([C@@H]1NCC=1C(=CC=C(C)C=1)OC)[H])C1=CC=CC=C1 GKJVNRHHOMPGSG-NSIYGSDQSA-N 0.000 claims description 2
ZBFJTKASKIUJNF-PHXFNYRRSA-N (2s,3s,4s,5r)-2-benzhydryl-3-[(2-methoxy-5-methylsulfinylphenyl)methylamino]-1-azabicyclo[2.2.2]octane-5-carboxylic acid Chemical compound C=1C=CC=CC=1C([C@@H]1N2CC[C@@]([C@H](C2)C(O)=O)([C@@H]1NCC=1C(=CC=C(C=1)S(C)=O)OC)[H])C1=CC=CC=C1 ZBFJTKASKIUJNF-PHXFNYRRSA-N 0.000 claims description 2
NNQJDQUAJJRYRV-NSIYGSDQSA-N (2s,3s,4s,5r)-2-benzhydryl-3-[(2-methoxy-5-methylsulfonylphenyl)methylamino]-1-azabicyclo[2.2.2]octane-5-carboxylic acid Chemical compound C=1C=CC=CC=1C([C@@H]1N2CC[C@@]([C@H](C2)C(O)=O)([C@@H]1NCC=1C(=CC=C(C=1)S(C)(=O)=O)OC)[H])C1=CC=CC=C1 NNQJDQUAJJRYRV-NSIYGSDQSA-N 0.000 claims description 2
UGYNIDYASJFWTR-FXZOGHEHSA-N (2s,3s,4s,5r)-2-benzhydryl-3-[(2-methoxy-5-propan-2-ylphenyl)methylamino]-1-azabicyclo[2.2.2]octane-5-carboxylic acid Chemical compound C=1C=CC=CC=1C([C@@H]1N2CC[C@@]([C@H](C2)C(O)=O)([C@@H]1NCC=1C(=CC=C(C=1)C(C)C)OC)[H])C1=CC=CC=C1 UGYNIDYASJFWTR-FXZOGHEHSA-N 0.000 claims description 2
UCSKUOLGIXJPLU-FXZOGHEHSA-N (2s,3s,4s,5r)-2-benzhydryl-3-[(2-methoxy-5-propylphenyl)methylamino]-1-azabicyclo[2.2.2]octane-5-carboxylic acid Chemical compound C=1C=CC=CC=1C([C@@H]1N2CC[C@@]([C@H](C2)C(O)=O)([C@@H]1NCC=1C(=CC=C(CCC)C=1)OC)[H])C1=CC=CC=C1 UCSKUOLGIXJPLU-FXZOGHEHSA-N 0.000 claims description 2
FQMDWRVWAZOFJF-QUNNAWRHSA-N (2s,3s,4s,5r)-2-benzhydryl-3-[(5-butan-2-yl-2-methoxyphenyl)methylamino]-1-azabicyclo[2.2.2]octane-5-carboxylic acid Chemical compound C=1C=CC=CC=1C([C@@H]1N2CC[C@@]([C@H](C2)C(O)=O)([C@@H]1NCC=1C(=CC=C(C=1)C(C)CC)OC)[H])C1=CC=CC=C1 FQMDWRVWAZOFJF-QUNNAWRHSA-N 0.000 claims description 2
NOTNLZQKHMFVKX-MTDVLGRSSA-N (2s,3s,4s,5r)-2-benzhydryl-3-[(6-methoxy-6-methylsulfanylcyclohexa-2,4-dien-1-yl)methylamino]-1-azabicyclo[2.2.2]octane-5-carboxylic acid Chemical compound C=1C=CC=CC=1C([C@@H]1N2CC[C@@]([C@H](C2)C(O)=O)([C@@H]1NCC1C(C=CC=C1)(OC)SC)[H])C1=CC=CC=C1 NOTNLZQKHMFVKX-MTDVLGRSSA-N 0.000 claims description 2
LVCKDBYHCLGPDR-LSGCGUROSA-N (2s,3s,4s,5r)-2-benzhydryl-3-[[2-methoxy-5-(trifluoromethoxy)phenyl]methylamino]-1-azabicyclo[2.2.2]octane-5-carboxylic acid Chemical compound C=1C=CC=CC=1C([C@@H]1N2CC[C@@]([C@H](C2)C(O)=O)([C@@H]1NCC=1C(=CC=C(OC(F)(F)F)C=1)OC)[H])C1=CC=CC=C1 LVCKDBYHCLGPDR-LSGCGUROSA-N 0.000 claims description 2
LBYSHULELVFOGE-ATACATFBSA-N (2s,3s,4s,5r)-2-benzhydryl-3-[[5-(dimethylamino)-2-methoxyphenyl]methylamino]-1-azabicyclo[2.2.2]octane-5-carboxylic acid Chemical compound C=1C=CC=CC=1C([C@@H]1N2CC[C@@]([C@H](C2)C(O)=O)([C@@H]1NCC=1C(=CC=C(C=1)N(C)C)OC)[H])C1=CC=CC=C1 LBYSHULELVFOGE-ATACATFBSA-N 0.000 claims description 2
DKWJWICVVLNEFV-UHFFFAOYSA-N 2-benzhydryl-n-[2-methoxy-5-(trifluoromethoxy)phenyl]-2-methyl-1-azabicyclo[2.2.2]octan-3-amine Chemical compound COC1=CC=C(OC(F)(F)F)C=C1NC1C(C(C=2C=CC=CC=2)C=2C=CC=CC=2)(C)N2CCC1CC2 DKWJWICVVLNEFV-UHFFFAOYSA-N 0.000 claims description 2
125000006499 2-trifluoromethoxy benzyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
HIORMPAWFMQDOW-ZCYQVOJMSA-N 6-[(2s,3s)-3-[(2-methoxyphenyl)methylamino]-2-phenylpiperidin-1-yl]hexan-1-ol Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)N(CCCCCCO)CCC1 HIORMPAWFMQDOW-ZCYQVOJMSA-N 0.000 claims description 2
ZGACJMVLEGDHNP-CWAVIJBDSA-N CC(C)CNC(C=C1)=CC(CN[C@@H]2[C@H](C3=CC=CC=C3)NCCC2)=C1OC(C)C.CC(N=C(C)S1)=C1S(O)(=O)=O Chemical compound CC(C)CNC(C=C1)=CC(CN[C@@H]2[C@H](C3=CC=CC=C3)NCCC2)=C1OC(C)C.CC(N=C(C)S1)=C1S(O)(=O)=O ZGACJMVLEGDHNP-CWAVIJBDSA-N 0.000 claims description 2
OXVZEEKXZNKIKY-IUQUCOCYSA-N CC(C)CNC(C=C1)=CC(CN[C@@H]2[C@H](C3=CC=CC=C3)NCCC2)=C1OC.CC(N=C(C)S1)=C1S(O)(=O)=O Chemical compound CC(C)CNC(C=C1)=CC(CN[C@@H]2[C@H](C3=CC=CC=C3)NCCC2)=C1OC.CC(N=C(C)S1)=C1S(O)(=O)=O OXVZEEKXZNKIKY-IUQUCOCYSA-N 0.000 claims description 2
HGPNOJKZSWSOKK-XYOGLKKJSA-N CC(C)NC(C=C1)=CC(CN[C@@H]2[C@H](C3=CC=CC=C3)NCCC2)=C1OC(C)C.CC(N=C(C)S1)=C1S(O)(=O)=O Chemical compound CC(C)NC(C=C1)=CC(CN[C@@H]2[C@H](C3=CC=CC=C3)NCCC2)=C1OC(C)C.CC(N=C(C)S1)=C1S(O)(=O)=O HGPNOJKZSWSOKK-XYOGLKKJSA-N 0.000 claims description 2
241000283086 Equidae Species 0.000 claims description 2
241000282326 Felis catus Species 0.000 claims description 2
150000001412 amines Chemical class 0.000 claims description 2
JGCMPBRNZDBPGS-IGKIAQTJSA-N ethyl 6-[(2s,3s)-3-[(2-methoxyphenyl)methylamino]-2-phenylpiperidin-1-yl]hexanoate Chemical compound N([C@H]1CCCN([C@H]1C=1C=CC=CC=1)CCCCCC(=O)OCC)CC1=CC=CC=C1OC JGCMPBRNZDBPGS-IGKIAQTJSA-N 0.000 claims description 2
KXCUGLQCBUEEQE-AHWVRZQESA-N n,2,4-trimethyl-n-[3-[[[(2s,3s)-2-phenylpiperidin-3-yl]amino]methyl]-4-propan-2-yloxyphenyl]-1,3-thiazole-5-sulfonamide Chemical compound C1([C@@H]2NCCC[C@@H]2NCC2=CC(=CC=C2OC(C)C)N(C)S(=O)(=O)C2=C(N=C(C)S2)C)=CC=CC=C1 KXCUGLQCBUEEQE-AHWVRZQESA-N 0.000 claims description 2
XXXAPFHGQOEKLI-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-2,4-diphenylpiperidin-3-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NCCC1C1=CC=CC=C1 XXXAPFHGQOEKLI-UHFFFAOYSA-N 0.000 claims description 2
SZFRAFLMDAIGLU-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-4-methyl-2-phenylpiperidin-3-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NCCC1C SZFRAFLMDAIGLU-UHFFFAOYSA-N 0.000 claims description 2
MYORKKSQSYUQSH-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-5-methyl-2-phenylpiperidin-3-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NCC(C)C1 MYORKKSQSYUQSH-UHFFFAOYSA-N 0.000 claims description 2
DBKJGIXLYZJDMI-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-6-methyl-2-phenylpiperidin-3-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NC(C)CC1 DBKJGIXLYZJDMI-UHFFFAOYSA-N 0.000 claims description 2
VWNODFQKKKCTRU-AHWVRZQESA-N n-[4-methoxy-3-[[[(2s,3s)-2-phenylpiperidin-3-yl]amino]methyl]phenyl]-2,4-dimethyl-n-propan-2-yl-1,3-thiazole-5-sulfonamide Chemical compound C1([C@@H]2NCCC[C@@H]2NCC2=CC(=CC=C2OC)N(C(C)C)S(=O)(=O)C2=C(N=C(C)S2)C)=CC=CC=C1 VWNODFQKKKCTRU-AHWVRZQESA-N 0.000 claims description 2
GLTOZQQTCQHDOH-UPVQGACJSA-N n-[4-methoxy-3-[[[(2s,3s)-2-phenylpiperidin-3-yl]amino]methyl]phenyl]-n,2,4-trimethyl-1,3-thiazole-5-sulfonamide Chemical compound C1([C@@H]2NCCC[C@@H]2NCC2=CC(=CC=C2OC)N(C)S(=O)(=O)C2=C(N=C(C)S2)C)=CC=CC=C1 GLTOZQQTCQHDOH-UPVQGACJSA-N 0.000 claims description 2
LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 claims description 2
QFTQKCRAJOXJNK-DKJKITOUSA-N (2s,3s)-2-benzhydryl-n-(5-butan-2-yl-2-methoxyphenyl)-2-methyl-1-azabicyclo[2.2.2]octan-3-amine Chemical compound CCC(C)C1=CC=C(OC)C(N[C@@H]2[C@](N3CCC2CC3)(C)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 QFTQKCRAJOXJNK-DKJKITOUSA-N 0.000 claims 1
NNNAFENHFFKFSL-KBXCAEBGSA-N (2s,3s)-3-[[2-(difluoromethoxy)-5-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-1-amine Chemical compound C([C@@H]1CCCN([C@@H]1C=1C=CC=CC=1)N)C1=CC(OC(F)(F)F)=CC=C1OC(F)F NNNAFENHFFKFSL-KBXCAEBGSA-N 0.000 claims 1
BTXTTXHHCNFOGR-HNAYVOBHSA-N (2s,3s)-3-[[5-chloro-2-(2,2,2-trifluoroethoxy)phenyl]methyl]-2-phenylpiperidin-1-amine Chemical compound C([C@@H]1CCCN([C@@H]1C=1C=CC=CC=1)N)C1=CC(Cl)=CC=C1OCC(F)(F)F BTXTTXHHCNFOGR-HNAYVOBHSA-N 0.000 claims 1
HDGOKGLEAJIUED-LAUBAEHRSA-N (2s,3s)-3-[[5-tert-butyl-2-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-1-amine Chemical compound CC(C)(C)C1=CC=C(OC(F)(F)F)C(C[C@H]2[C@H](N(N)CCC2)C=2C=CC=CC=2)=C1 HDGOKGLEAJIUED-LAUBAEHRSA-N 0.000 claims 1
BXCXPWYLAUEXBY-IKFSTVPESA-N (2s,3s,4s,5r)-2-benzhydryl-3-[(2,5-dimethoxyphenyl)methylamino]-n,n-diethyl-1-azabicyclo[2.2.2]octane-5-carboxamide Chemical compound C=1C=CC=CC=1C([C@@H]1N2CC[C@@]([C@H](C2)C(=O)N(CC)CC)([C@@H]1NCC=1C(=CC=C(OC)C=1)OC)[H])C1=CC=CC=C1 BXCXPWYLAUEXBY-IKFSTVPESA-N 0.000 claims 1
HANWCAQDYMDUKN-ATACATFBSA-N (2s,3s,4s,5r)-2-benzhydryl-3-[(5-ethyl-2-methoxyphenyl)methylamino]-1-azabicyclo[2.2.2]octane-5-carboxylic acid Chemical compound C=1C=CC=CC=1C([C@@H]1N2CC[C@@]([C@H](C2)C(O)=O)([C@@H]1NCC=1C(=CC=C(CC)C=1)OC)[H])C1=CC=CC=C1 HANWCAQDYMDUKN-ATACATFBSA-N 0.000 claims 1
WUSKHOUAANEBFY-HPZMQGABSA-N 6-[(2s,3s)-3-[(2-methoxyphenyl)methylamino]-2-phenylpiperidin-1-yl]hexane-1,2-diol Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)N(CCCCC(O)CO)CCC1 WUSKHOUAANEBFY-HPZMQGABSA-N 0.000 claims 1
AXNWANHXOICNMX-QQTWVUFVSA-N CC1=C(C)SC(S(O)(=O)=O)=N1.CNC(C=C1)=CC(CN[C@@H]2[C@H](C3=CC=CC=C3)NCCC2)=C1OC(F)(F)F Chemical compound CC1=C(C)SC(S(O)(=O)=O)=N1.CNC(C=C1)=CC(CN[C@@H]2[C@H](C3=CC=CC=C3)NCCC2)=C1OC(F)(F)F AXNWANHXOICNMX-QQTWVUFVSA-N 0.000 claims 1
102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 claims 1
101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 claims 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
LHUWCDDBFUABOQ-WEZIJMHWSA-N n-[4-[(2s,3s)-3-[(2-methoxyphenyl)methylamino]-2-phenylpiperidin-1-yl]butyl]naphthalene-2-carboxamide Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)N(CCCCNC(=O)C=2C=C3C=CC=CC3=CC=2)CCC1 LHUWCDDBFUABOQ-WEZIJMHWSA-N 0.000 claims 1
UQCMZYGKYBKFKH-GMAHTHKFSA-N n-[4-methoxy-3-[[[(2s,3s)-2-phenylpiperidin-3-yl]amino]methyl]phenyl]-4,5-dimethyl-1,3-thiazol-2-amine Chemical compound C1=C(CN[C@@H]2[C@@H](NCCC2)C=2C=CC=CC=2)C(OC)=CC=C1NC1=NC(C)=C(C)S1 UQCMZYGKYBKFKH-GMAHTHKFSA-N 0.000 claims 1
239000000902 placebo Substances 0.000 description 26
229940068196 placebo Drugs 0.000 description 26
230000006399 behavior Effects 0.000 description 24
230000000638 stimulation Effects 0.000 description 13
238000006243 chemical reaction Methods 0.000 description 10
208000000810 Separation Anxiety Diseases 0.000 description 7
241000894007 species Species 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
239000002775 capsule Substances 0.000 description 6
208000035475 disorder Diseases 0.000 description 6
102100024304 Protachykinin-1 Human genes 0.000 description 5
102000003141 Tachykinin Human genes 0.000 description 5
230000003542 behavioural effect Effects 0.000 description 5
238000002955 isolation Methods 0.000 description 5
230000009191 jumping Effects 0.000 description 5
238000009987 spinning Methods 0.000 description 5
108060008037 tachykinin Proteins 0.000 description 5
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
229940079593 drug Drugs 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000000203 mixture Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 3
LLSKXGRDUPMXLC-UHFFFAOYSA-N 1-phenylpiperidine Chemical compound C1CCCCN1C1=CC=CC=C1 LLSKXGRDUPMXLC-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
206010016275 Fear Diseases 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
101800003906 Substance P Proteins 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000008121 dextrose Substances 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
235000013305 food Nutrition 0.000 description 3
230000004044 response Effects 0.000 description 3
238000010254 subcutaneous injection Methods 0.000 description 3
239000007929 subcutaneous injection Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
230000000007 visual effect Effects 0.000 description 3
YSEQNZOXHCKLOG-UHFFFAOYSA-N 2-methyl-octanoic acid Chemical compound CCCCCCC(C)C(O)=O YSEQNZOXHCKLOG-UHFFFAOYSA-N 0.000 description 2
206010000117 Abnormal behaviour Diseases 0.000 description 2
206010001488 Aggression Diseases 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
241000282465 Canis Species 0.000 description 2
GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 2
229920000858 Cyclodextrin Polymers 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 2
GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 2
206010039424 Salivary hypersecretion Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
206010044565 Tremor Diseases 0.000 description 2
208000012761 aggressive behavior Diseases 0.000 description 2
230000016571 aggressive behavior Effects 0.000 description 2
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
208000022531 anorexia Diseases 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
238000009227 behaviour therapy Methods 0.000 description 2
210000000941 bile Anatomy 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
229960004606 clomipramine Drugs 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
206010061428 decreased appetite Diseases 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000002674 ointment Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
125000001151 peptidyl group Chemical group 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229940001470 psychoactive drug Drugs 0.000 description 2
239000004089 psychotropic agent Substances 0.000 description 2
208000026451 salivation Diseases 0.000 description 2
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
201000000980 schizophrenia Diseases 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 2
239000003826 tablet Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
238000004448 titration Methods 0.000 description 2
238000012549 training Methods 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
YLTSJRYNMXORGD-WIOPSUGQSA-N (2S,3S)-3-[(2-methoxy-5-phenylphenyl)methyl]-2-phenylpiperidin-1-amine Chemical compound COc1ccc(cc1C[C@@H]1CCCN(N)[C@@H]1c1ccccc1)-c1ccccc1 YLTSJRYNMXORGD-WIOPSUGQSA-N 0.000 description 1
XOKWAQNXHVJYLG-GHTZIAJQSA-N (2S,3S)-3-[(5-ethyl-2-methoxyphenyl)methyl]-2-phenylpiperidin-1-amine Chemical compound CCc1ccc(OC)c(C[C@@H]2CCCN(N)[C@@H]2c2ccccc2)c1 XOKWAQNXHVJYLG-GHTZIAJQSA-N 0.000 description 1
JTJPCHFQFYWZCZ-HKUYNNGSSA-N (2S,3S)-N-[[5-(methylamino)-2-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound CNC1=CC=C(OC(F)(F)F)C(CN[C@@H]2[C@@H](NCCC2)C=2C=CC=CC=2)=C1 JTJPCHFQFYWZCZ-HKUYNNGSSA-N 0.000 description 1
SFTQTBLXIWAZMI-UPVQGACJSA-N (2s,3s)-1-(5-aminopentyl)-n-[(2-methoxyphenyl)methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)N(CCCCCN)CCC1 SFTQTBLXIWAZMI-UPVQGACJSA-N 0.000 description 1
IWNUVCPVRJASIF-CONSDPRKSA-N (2s,3s)-2-benzhydryl-n-(2-methoxy-5-propan-2-ylphenyl)-2-methyl-1-azabicyclo[2.2.2]octan-3-amine Chemical compound COC1=CC=C(C(C)C)C=C1N[C@@H]1[C@@](C(C=2C=CC=CC=2)C=2C=CC=CC=2)(C)N2CCC1CC2 IWNUVCPVRJASIF-CONSDPRKSA-N 0.000 description 1
CLEMOHZZIAAIFC-CONSDPRKSA-N (2s,3s)-2-benzhydryl-n-(2-methoxy-5-propylphenyl)-2-methyl-1-azabicyclo[2.2.2]octan-3-amine Chemical compound CCCC1=CC=C(OC)C(N[C@@H]2[C@](N3CCC2CC3)(C)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 CLEMOHZZIAAIFC-CONSDPRKSA-N 0.000 description 1
GFMAFYNUQDLPBP-QWRGUYRKSA-N (2s,3s)-2-phenylpiperidin-3-amine Chemical compound N[C@H]1CCCN[C@H]1C1=CC=CC=C1 GFMAFYNUQDLPBP-QWRGUYRKSA-N 0.000 description 1
WGUXMAYJVLIEJC-SIKLNZKXSA-N (2s,3s)-3-[(2-methoxy-5-propan-2-ylphenyl)methyl]-2-phenylpiperidin-1-amine Chemical compound COC1=CC=C(C(C)C)C=C1C[C@H]1[C@@H](C=2C=CC=CC=2)N(N)CCC1 WGUXMAYJVLIEJC-SIKLNZKXSA-N 0.000 description 1
RMORKLGEDQLZJK-SIKLNZKXSA-N (2s,3s)-3-[(2-methoxy-5-propylphenyl)methyl]-2-phenylpiperidin-1-amine Chemical compound CCCC1=CC=C(OC)C(C[C@H]2[C@H](N(N)CCC2)C=2C=CC=CC=2)=C1 RMORKLGEDQLZJK-SIKLNZKXSA-N 0.000 description 1
BIXFYVZGYCPPHC-NZQKXSOJSA-N (2s,3s)-3-[(5-butyl-2-methoxyphenyl)methyl]-2-phenylpiperidin-1-amine Chemical compound CCCCC1=CC=C(OC)C(C[C@H]2[C@H](N(N)CCC2)C=2C=CC=CC=2)=C1 BIXFYVZGYCPPHC-NZQKXSOJSA-N 0.000 description 1
QVGXCMWXTJZSOB-AOMKIAJQSA-N (2s,3s)-3-[(5-tert-butyl-2-methoxyphenyl)methyl]-2-[3-(trifluoromethoxy)phenyl]piperidin-1-amine Chemical compound COC1=CC=C(C(C)(C)C)C=C1C[C@H]1[C@@H](C=2C=C(OC(F)(F)F)C=CC=2)N(N)CCC1 QVGXCMWXTJZSOB-AOMKIAJQSA-N 0.000 description 1
LXDZLOATCVUXHT-PGRDOPGGSA-N (2s,3s)-3-[(5-tert-butyl-2-methoxyphenyl)methyl]-2-phenylpiperidin-1-amine Chemical compound COC1=CC=C(C(C)(C)C)C=C1C[C@H]1[C@@H](C=2C=CC=CC=2)N(N)CCC1 LXDZLOATCVUXHT-PGRDOPGGSA-N 0.000 description 1
RVXVTPXAIUDORO-OXJNMPFZSA-N (2s,3s)-3-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-1-amine Chemical compound CCOC1=CC=C(OC(F)(F)F)C=C1C[C@H]1[C@@H](C=2C=CC=CC=2)N(N)CCC1 RVXVTPXAIUDORO-OXJNMPFZSA-N 0.000 description 1
VWDNLKIXTQMOLA-DHLKQENFSA-N (2s,3s)-n-[[5-[(4,5-dimethyl-1,3-thiazol-2-yl)methylamino]-2-methoxyphenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound C1=C(CN[C@@H]2[C@@H](NCCC2)C=2C=CC=CC=2)C(OC)=CC=C1NCC1=NC(C)=C(C)S1 VWDNLKIXTQMOLA-DHLKQENFSA-N 0.000 description 1
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 description 1
HQZONHWUUKPDRH-QGWOSTIUSA-N 4-[(2s,3s)-3-[(2-methoxyphenyl)methylamino]-2-phenylpiperidin-1-yl]-1-phenylbutan-1-ol Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)N(CCCC(O)C=2C=CC=CC=2)CCC1 HQZONHWUUKPDRH-QGWOSTIUSA-N 0.000 description 1
LAOMAAZAXGILTO-WNJJXGMVSA-N 4-[(2s,3s)-3-[(2-methoxyphenyl)methylamino]-2-phenylpiperidin-1-yl]-1-phenylbutan-1-one Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)N(CCCC(=O)C=2C=CC=CC=2)CCC1 LAOMAAZAXGILTO-WNJJXGMVSA-N 0.000 description 1
241000824799 Canis lupus dingo Species 0.000 description 1
241000252203 Clupea harengus Species 0.000 description 1
208000006561 Cluster Headache Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
206010015548 Euthanasia Diseases 0.000 description 1
208000001640 Fibromyalgia Diseases 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
206010020710 Hyperphagia Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010024264 Lethargy Diseases 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
102400000097 Neurokinin A Human genes 0.000 description 1
101800000399 Neurokinin A Proteins 0.000 description 1
HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 description 1
102000046798 Neurokinin B Human genes 0.000 description 1
NHXYSAFTNPANFK-HDMCBQFHSA-N Neurokinin B Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(O)=O)C1=CC=CC=C1 NHXYSAFTNPANFK-HDMCBQFHSA-N 0.000 description 1
101800002813 Neurokinin-B Proteins 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
208000004880 Polyuria Diseases 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
102000007124 Tachykinin Receptors Human genes 0.000 description 1
108010072901 Tachykinin Receptors Proteins 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
229960005054 acepromazine Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
229960000836 amitriptyline Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
230000010397 anxiety-related behavior Effects 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
231100000871 behavioral problem Toxicity 0.000 description 1
238000013542 behavioral therapy Methods 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
229960002495 buspirone Drugs 0.000 description 1
QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
239000000969 carrier Substances 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000018912 cluster headache syndrome Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000000586 desensitisation Methods 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229960002464 fluoxetine Drugs 0.000 description 1
229960000389 fluoxetine hydrochloride Drugs 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
230000035929 gnawing Effects 0.000 description 1
235000019514 herring Nutrition 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
239000013642 negative control Substances 0.000 description 1
239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
150000002990 phenothiazines Chemical class 0.000 description 1
150000004885 piperazines Chemical class 0.000 description 1
206010036067 polydipsia Diseases 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
208000022530 polyphagia Diseases 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
229940035613 prozac Drugs 0.000 description 1
SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
150000008584 quinuclidines Chemical class 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
238000007790 scraping Methods 0.000 description 1
238000006748 scratching Methods 0.000 description 1
230000002393 scratching effect Effects 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
239000003772 serotonin uptake inhibitor Substances 0.000 description 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
229960003660 sertraline hydrochloride Drugs 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
230000037321 sleepiness Effects 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960001790 sodium citrate Drugs 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
DYWSVUBJGFTOQC-UHFFFAOYSA-N xi-2-Ethylheptanoic acid Chemical compound CCCCCC(CC)C(O)=O DYWSVUBJGFTOQC-UHFFFAOYSA-N 0.000 description 1
229940020965 zoloft Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Emergency Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

SK25-2004A 2001-07-20 2002-07-15 Použitie antagonistov receptora NK-1 na výrobu liečiva na liečenie abnormálneho úzkostného správania domácich zvierat a spôsob screeningu skúšanej zlúčeniny s cieľom stanoviť anxiolytickú účinnosť u psov SK252004A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US30669201P	2001-07-20	2001-07-20
PCT/IB2002/002847 WO2003009848A1 (en)	2001-07-20	2002-07-15	Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses

Publications (1)

Publication Number	Publication Date
SK252004A3 true SK252004A3 (sk)	2005-03-04

Family

ID=23186426

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK25-2004A SK252004A3 (sk)	2001-07-20	2002-07-15	Použitie antagonistov receptora NK-1 na výrobu liečiva na liečenie abnormálneho úzkostného správania domácich zvierat a spôsob screeningu skúšanej zlúčeniny s cieľom stanoviť anxiolytickú účinnosť u psov

Country Status (13)

Country	Link
US (1)	US20030139443A1 (cs)
EP (1)	EP1411946A1 (cs)
JP (1)	JP2005504029A (cs)
KR (1)	KR20040029375A (cs)
CN (1)	CN1529600A (cs)
CA (1)	CA2448722A1 (cs)
CZ (1)	CZ200434A3 (cs)
HU (1)	HUP0401154A2 (cs)
IL (1)	IL158990A0 (cs)
PL (1)	PL367944A1 (cs)
SK (1)	SK252004A3 (cs)
WO (1)	WO2003009848A1 (cs)
ZA (1)	ZA200308991B (cs)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2554823A1 (en) *	2004-01-30	2005-09-09	Pfizer Products Inc.	Nk-1 receptor antagonists to improve anesthesia recovery
LT1713504T (lt) *	2004-01-30	2017-09-11	Zoetis Services Llc	Antimikrobinis konservantas, skirtas multi-dozinėms kompozicijoms, panaudojant beta-ciklodekstrinus, skirtas skystoms vaisto formoms
US7459450B2 (en) *	2004-04-30	2008-12-02	Schering Corporation	Neuropeptide receptor modulators
CN114403042A (zh) *	2021-12-13	2022-04-29	深圳先进技术研究院	一种大动物焦虑症动物模型

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1990005525A1 (en) *	1988-11-23	1990-05-31	Pfizer Inc.	Quinuclidine derivatives as substance p antagonists
US5232929A (en) *	1990-11-28	1993-08-03	Pfizer Inc.	3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
FR2677361A1 (fr) *	1991-06-04	1992-12-11	Adir	Nouveaux peptides et pseudopeptides, derives de tachykinines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE9290063U1 (de) *	1991-05-31	1994-02-24	Pfizer Inc., New York, N.Y.	Chinuclidin-Derivate
BR9206161A (pt) *	1991-06-20	1995-10-31	Pfizer	Derivados fluoroalcoxibenzilamino de heterociclos contendo nitrogénio
JP2832754B2 (ja) *	1993-03-04	1998-12-09	ファイザー・インク．	サブスタンスｐアンタゴニストとしてのスピロアザ環式誘導体
EP0623344B1 (fr) *	1993-05-04	2000-07-26	Ceva Sante Animale	Utilisation de la Sélégiline en médecine vetérinaire
IL109646A0 (en) *	1993-05-19	1994-08-26	Pfizer	Heteroatom substituted alkyl benzylamino-quinuclidines
US5393762A (en) *	1993-06-04	1995-02-28	Pfizer Inc.	Pharmaceutical agents for treatment of emesis
US5703065A (en) *	1993-09-17	1997-12-30	Pfizer Inc.	Heteroarylamino and heteroarylsulfonamido substituted 3-benyzlaminomethyl piperidines and related compounds
US6083943A (en) *	1993-09-17	2000-07-04	Pfizer Inc	Substituted azaheterocyclecarboxylic acid
US5854262A (en) *	1993-10-07	1998-12-29	Pfizer Inc.	Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
PE45195A1 (es) *	1994-03-03	1996-01-17	Boehringer Ingelheim Kg	Derivado de aminoacido, procedimiento para su preparacion y composicion farmaceutica que lo contiene
US5607936A (en) *	1994-09-30	1997-03-04	Merck & Co., Inc.	Substituted aryl piperazines as neurokinin antagonists
ES2229259T3 (es) *	1995-01-12	2005-04-16	Glaxo Group Limited	Derivados de piperidina con actividad antagonista de taquiquinina.
US5990125A (en) *	1996-01-19	1999-11-23	Pfizer Inc.	NK-1 receptor antagonists for the treatment of cancer
ATE333879T1 (de) *	1996-10-07	2006-08-15	Merck Sharp & Dohme	Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
US6117855A (en) *	1996-10-07	2000-09-12	Merck Sharp & Dohme Ltd.	Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
JP4195512B2 (ja) *	1996-12-19	2008-12-10	アベンティス・ファーマスーティカルズ・インコーポレイテッド	新規な複素環置換ピロリジンアミド誘導体
US6156749A (en) *	1997-12-01	2000-12-05	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating movement disorders
JP4669095B2 (ja) *	1999-07-19	2011-04-13	太陽化学株式会社	ペットの問題行動抑制組成物
CA2280309C (en) *	1999-08-13	2007-05-08	William Norton Milgram	Use of adrafinil to treat behavioral problems in aged canines
CA2324813A1 (en) *	1999-11-10	2001-05-10	Susan Beth Sobolov-Jaynes	Combination treatment for depression and anxiety
US20020049211A1 (en) *	2000-09-06	2002-04-25	Sobolov-Jaynes Susan Beth	Combination treatment for depression and anxiety

2002
- 2002-07-15 CZ CZ200434A patent/CZ200434A3/cs unknown
- 2002-07-15 EP EP02745741A patent/EP1411946A1/en not_active Withdrawn
- 2002-07-15 SK SK25-2004A patent/SK252004A3/sk not_active Application Discontinuation
- 2002-07-15 IL IL15899002A patent/IL158990A0/xx unknown
- 2002-07-15 WO PCT/IB2002/002847 patent/WO2003009848A1/en not_active Ceased
- 2002-07-15 PL PL02367944A patent/PL367944A1/xx not_active Application Discontinuation
- 2002-07-15 JP JP2003515240A patent/JP2005504029A/ja not_active Withdrawn
- 2002-07-15 CA CA002448722A patent/CA2448722A1/en not_active Abandoned
- 2002-07-15 HU HU0401154A patent/HUP0401154A2/hu unknown
- 2002-07-15 KR KR10-2004-7000901A patent/KR20040029375A/ko not_active Ceased
- 2002-07-15 CN CNA028141873A patent/CN1529600A/zh active Pending
- 2002-07-19 US US10/199,284 patent/US20030139443A1/en not_active Abandoned
2003
- 2003-11-19 ZA ZA200308991A patent/ZA200308991B/en unknown

Also Published As

Publication number	Publication date
HUP0401154A2 (hu)	2004-10-28
CA2448722A1 (en)	2003-02-06
CZ200434A3 (cs)	2005-02-16
JP2005504029A (ja)	2005-02-10
US20030139443A1 (en)	2003-07-24
IL158990A0 (en)	2004-05-12
ZA200308991B (en)	2004-11-19
KR20040029375A (ko)	2004-04-06
EP1411946A1 (en)	2004-04-28
PL367944A1 (en)	2005-03-07
CN1529600A (zh)	2004-09-15
WO2003009848A1 (en)	2003-02-06

Legal Events

Date	Code	Title	Description
2012-09-03	FC9A	Refused patent application

Publication	Publication Date	Title
Robichaud et al.	2001	PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway
US10632116B2 (en)	2020-04-28	Combinations of serotonin receptor agonists for treatment of movement disorders
Fibiger et al.	1971	A biphasic action of central cholinergic stimulation on behavioral arousal in the rat
JPH08225464A (ja)	1996-09-03	嘔吐治療用ｎｋ−１受容体アンタゴニスト及び５ｈｔ３受容体アンタゴニスト
AU774117B2 (en)	2004-06-17	The use of certain affinity NMDA antagonists as antidepressants
US20220096449A1 (en)	2022-03-31	Method of treatment with tradipitant
CA2458855A1 (en)	2003-03-06	Composition for treating parkinson's disease containing a cb1 receptor antagonist and a product activating dopaminergic neurotransmission in the brain
Shaban et al.	2020	Evaluation of the antinociceptive effect of xylazine and it’s interaction with metoclopramide in the acute pain model in mice
KR20210107729A (ko)	2021-09-01	운동 장애의 치료
JP2009518423A (ja)	2009-05-07	統合失調症の副作用および陰性症状を治療するためのｃｂ１アンタゴニストの使用
US20080194631A1 (en)	2008-08-14	Medicament For the Treatment of Central Nervous System Disorders
Baran et al.	1994	The glycine/NMDA receptor partial agonist D-cycloserine blocks kainate-induced seizures in rats. Comparison with MK-801 and diazepam
SK252004A3 (sk)	2005-03-04	Použitie antagonistov receptora NK-1 na výrobu liečiva na liečenie abnormálneho úzkostného správania domácich zvierat a spôsob screeningu skúšanej zlúčeniny s cieľom stanoviť anxiolytickú účinnosť u psov
US4468391A (en)	1984-08-28	Combination of β-adrenoceptor antagonists and anxiolytic agents
DE102004063753A1 (de)	2006-07-13	Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
JP7588773B2 (ja)	2024-11-25	グルタミン酸２ｂ受容体拮抗薬及びシグマ受容体作動薬の鎮咳薬としての使用
AU2002317436A1 (en)	2003-02-17	Use of NK-1 receptor antagonists to modify unwanted behaviour in dogs, cats and horses
US6511982B2 (en)	2003-01-28	Treatment of pain
JP2000501709A (ja)	2000-02-15	疼痛治療用組成物
JP2005504029A5 (cs)	2005-09-22
Gruen et al.	2018	Drugs affecting animal behavior
RU2605283C2 (ru)	2016-12-20	Фармацевтическая композиция для лечения зависимости у людей
JP2019516758A (ja)	2019-06-20	不安障害を治療するための（２Ｓ）−１−［４−（３，４−ジクロロフェニル）ピペリジン−１−イル］−３−［２−（５−メチル−１，３，４−オキサジアゾール−２−イル）ベンゾ［ｂ］フラン−４−イルオキシ］プロパン−２−オールまたはその代謝産物
HK1065256A (en)	2005-02-18	Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses
JPH09110721A (ja)	1997-04-28	Ｎｋ−１受容体アンタゴニストを用いる抗嘔吐治療用の組み合わせ